Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis

SIMPLE SUMMARY: BRAF/MEK therapy and anti-PD-1 therapy have shown better recurrence-free survival of stage III melanoma in patients with BRAF V600 mutations in clinical trials. However, little is known about how these therapies compare to each other in everyday practice. The aim of our study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: De Meza, Melissa M., Blokx, Willeke A. M., Bonenkamp, Johannes J., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Boers-Sonderen, Marye J., De Groot, Jan Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen, Van Not, Olivier J., Piersma, Djura, Van Rijn, Rozemarijn S., Stevense-den Boer, Marion, Van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Van den Eertwegh, Alfonsus J. M., Suijkerbuijk, Karijn P. M., Wouters, Michel W. J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857200/
https://www.ncbi.nlm.nih.gov/pubmed/36672358
http://dx.doi.org/10.3390/cancers15020409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857200/
https://www.ncbi.nlm.nih.gov/pubmed/36672358
http://dx.doi.org/10.3390/cancers15020409

Ejemplares similares